Cargando…

Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study

About 15% of patients with non-small cell lung cancer (NSCLC) harbor the Kirsten rat sarcoma homolog G12C mutation (KRAS(G12C)). Selective KRAS(G12C) inhibitors offer new treatment opportunities, but little is known about the prevalence, characteristics, and outcomes of standard-of-care treatment (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Illini, Oliver, Fabikan, Hannah, Hochmair, Maximilian Johannes, Weinlinger, Christoph, Krenbek, Dagmar, Brcic, Luka, Setinek, Ulrike, Terbuch, Angelika, Absenger, Gudrun, Konjić, Selma, Valipour, Arschang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324356/ https://www.ncbi.nlm.nih.gov/pubmed/35887862 http://dx.doi.org/10.3390/jcm11144098

Ejemplares similares

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Effectiveness of Outpatient Pulmonary Rehabilitation in Patients with Surgically Resected Lung Cancer: A Retrospective Real-World Analysis
por: Illini, Oliver, et al.
Publicado: (2022)

Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients
por: Holzknecht, Arnulf, et al.
Publicado: (2022)

Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center experience
por: Zacharias, Martin, et al.
Publicado: (2021)

Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung
por: Brcic, Luka, et al.
Publicado: (2018)

Cancer Stem Cell-Like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung Cancer
por: Obermayr, Eva, et al.
Publicado: (2021)

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
por: Illini, Oliver, et al.
Publicado: (2022)

Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer
por: Obermayr, Eva, et al.
Publicado: (2019)

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
por: Illini, Oliver, et al.
Publicado: (2021)

Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature
por: Papaporfyriou, Anastasia, et al.
Publicado: (2021)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types
por: Robinson, Irina, et al.
Publicado: (2023)

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
por: Buder, Anna, et al.
Publicado: (2019)

ASCO update: lung cancer
por: Absenger, Gudrun, et al.
Publicado: (2017)

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
por: Hackner, Klaus, et al.
Publicado: (2021)

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients
por: Buder, Anna, et al.
Publicado: (2021)

Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review
por: Huf, Waltraud Elisabeth, et al.
Publicado: (2023)

Modern Bronchoscopic Treatment Options for Patients with Chronic Bronchitis
por: Mayr, Anna Katharina, et al.
Publicado: (2023)

“Nitrogen Wash-Out” in Non-Hypoxaemic Patients with Spontaneous Pneumothorax: A Narrative Review
por: Grasmuk-Siegl, Erwin, et al.
Publicado: (2023)

Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines
por: Hochmair, Maximilian, et al.
Publicado: (2019)

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells
por: Plangger, Adelina, et al.
Publicado: (2021)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy
por: Bakeer, Mostafa, et al.
Publicado: (2020)

Swiss Experience in Therapy With Dual Bronchodilation in Chronic Obstructive Pulmonary Disease in Relation to Self-Reported Physical Functionality
por: Spielmanns, Marc, et al.
Publicado: (2021)

Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
por: Plangger, Adelina, et al.
Publicado: (2022)

Next Generation Cancer Vaccines—Make It Personal!
por: Terbuch, Angelika, et al.
Publicado: (2018)

Assessment of Patient Experiences with Respimat(®) in Everyday Clinical Practice
por: Taube, Christian, et al.
Publicado: (2020)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
por: Totschnig, David, et al.
Publicado: (2022)

RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD
por: Koblizek, Vladimir, et al.
Publicado: (2023)

The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner
por: Meinhardt, Anna-Lena, et al.
Publicado: (2022)

Chronisch-obstruktive Lungenerkrankung 2021 – die richtige Therapie für den richtigen Patienten
por: Olschewski, Horst, et al.
Publicado: (2021)

Organizing pneumonia following Covid19 pneumonia
por: Funk, Georg-Christian, et al.
Publicado: (2021)

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
por: Hochmair, Maximilian
Publicado: (2018)

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
por: Riedl, Jakob M., et al.
Publicado: (2020)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

Resistance to chemoimmunotherapy in non-small-cell lung cancer
por: Hochmair, Maximilian Johannes
Publicado: (2020)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
por: Brcic, Luka, et al.
Publicado: (2020)

Diagnosis and Molecular Profiles of Large Cell Neuroendocrine Carcinoma With Potential Targets for Therapy
por: Popper, Helmut, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8nric775h4p0vpf7a5ntfb3cuj